Naratriptan

Drug #1705

Naratriptan is a selective serotonin (5HT-1) agonist, similar to sumatriptan. Naratriptan is given orally only in the treatment of acute migraine attacks, it should not be used for the prophylaxis of migraine. It may be used during the established headache phase of an attack and is the preferred treatment in those who fail to respond to conventiaonal therapy.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Indole.

Molecular Weight: 371.9 · Non-proprietary name: Naratriptan.

Pharmacokinetics

Absorption: Naratriptan has an oral bioavailability is 63% (±9%).

Distribution: Naratriptan has a volume of distribution is 2.64(2.43-2.86)l/kg. plasma protein binding is 29.5(28-31)%.

Elimination: it is metabolised via hepatic, plasma half-life is 6hr, renal excretion is 50%.

Indications

Naratriptan is primarily indicated in conditions like Migraine.

Contraindications

Naratriptan is contraindicated in conditions like Peripheral vascular disease, Ischaemic heart disease, Uncontrolled hypertension, Adjunct in treatment of opioid dependance, Chronic intractable hypoglycaemia.

Dosage

Naratriptan's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
1.75 mg	1.75 mg	—	PO	If the migraine comes back after being relieved, another dose may be taken four hours after the last dose. Do not take more than 5 mg in any twenty-four-hour period (one day).
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

10 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Naratriptan is known to cause more or less tolerable side effects which are usually transient. These include Bradycardia or tachycardia, Dizziness, Dysuria, Fatigue, Flushing, Heaviness, Nausea and vomiting, Tightness of any part of body, Tingling .

Warnings / Precautions

5HT1 agonists (e.g Naratriptan) should be used with caution in conditions which predispose to coronary artery disease (pre-existing cardiac disease), pregnancy and breast-feeding. 5HT1 agonists are recommended as monotherapy and should not be taken concurrently with other acute migraine therapies. Little information is available on the use of these drugs in the elderly (over 65 year). Caution is also required in mild or moderate hepatic impairment; sensitivity to sulphonamides.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs

1 mg 2.5 mg

Drug Classification

1.7.1 — Acute migraine attack

Manufacturers

Manufacturers of Naratriptan in Pakistan:

S.J.& G